The nicotinic acid receptor - A new mechanism for an old drug

Lancet

Volumn 363, Issue 9424, 2004, Pages 1892-1894

  Karpe, Fredrik ^a   Frayn, Keith N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; INSULIN; LIPID; LIPOPROTEIN; NICOTINIC ACID;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATTY ACID BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; LIPOLYSIS; MYOPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 2942564118     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16359-9     Document Type: Short Survey

References (26)

1. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 278:2003;9869-9874
2. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 9:2003;352-355
3. Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acid: demonstration of a metabolic type of sympathicolysis. Acta Med Scand. 172:1962;641-645
4. Carlson LA, Hanngren Å. Initial distribution in mice of 3h-labeled nicotinic acid studied with autoradiography. Life Sci. 74:1964;867-871
5. Lorenzen A, Stannek C, Lang H, Andrianov V, Kalvinsh I, Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol. 59:2001;349-357
6. Schaub A, Futterer A, Pfeffer K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol. 31:2001;3714-3725
7. Nomura H, Nielsen BW, Matsushima K. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int Immunol. 5:1993;1239-1249
8. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci. 24:2003;276-283
9. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 88:1991;2059-2066
10. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 67:2004;411-419
11. The Coronary Drug Project Study Group. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381
12. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255
13. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418
14. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:1963;785-789
15. Davoren PM, Alberti KGMM. The effect of 24-hour suppression of plasma non-esterified fatty acid levels on glucose and lipid metabolism in NIDDM. Diab Nutr Metab. 8:1995;17-23
16. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes. 41:1992;1400-1408
17. Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab. 78:1994;717-721
18. Kumar S, Durrington PN, Bhatnagar D, Laing I. Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome. Lancet. 343:1994;1073-1074
19. Hawkins M, Tonelli J, Kishore P, et al. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes. 52:2003;2748-2758
20. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51:2002;7-18
21. Frayn KN. The glucose-fatty acid cycle: a physiological perspective. Biochem Soc Trans. 31:2003;1115-1119
22. Greenough WB 3rd, Crespin SR, Steinberg D. Hypoglycaemia and hyperinsulinaemia in response to raised free-fatty-acid levels. Lancet 1967; 2: 1334-1336.
23. Beysen C, Karpe F, Fielding BA, Clark A, Levy JC, Frayn KN. Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia. 45:2002;1533-1541
24. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 42:1999;128-138
25. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia. 38:1995;1213-1217
26. Charles MA, Eschwege E, Thibult N, et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia. 40:1997;1101-1106